Literature DB >> 24210111

AAVPG: a vigilant vector where transgene expression is induced by p53.

Marcio C Bajgelman1, Ruan F V Medrano, Anna Carolina P V Carvalho, Bryan E Strauss.   

Abstract

Using p53 to drive transgene expression from viral vectors may provide on demand expression in response to physiologic stress, such as hypoxia or DNA damage. Here we introduce AAVPG, an adeno-associated viral (AAV) vector where a p53-responsive promoter, termed PG, is used to control transgene expression. In vitro assays show that expression from the AAVPG-luc vector was induced specifically in the presence of functional p53 (1038±202 fold increase, p<0.001). The AAVPG-luc vector was an effective biosensor of p53 activation in response to hypoxia (4.48±0.6 fold increase in the presence of 250µM CoCl2, p<0.001) and biomechanical stress (2.53±0.4 fold increase with stretching, p<0.05). In vivo, the vigilant nature of the AAVPG-luc vector was revealed after treatment of tumor-bearing mice with doxorubicin (pre-treatment, 3.4×10(5)±0.43×10(5)photons/s; post-treatment, 6.6×10(5)±2.1×10(5)photons/s, p<0.05). These results indicate that the AAVPG vector is an interesting option for detecting p53 activity both in vitro and in vivo.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenoassociated virus; Bioluminescence imaging; Doxorubicin; Gene regulation; Gene therapy; Hypoxia; Mechanical stress; Physiologic stress; Viral vector; p53

Mesh:

Substances:

Year:  2013        PMID: 24210111     DOI: 10.1016/j.virol.2013.09.004

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  4 in total

1.  Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth.

Authors:  Rodrigo Esaki Tamura; Marlous G Lana; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  Gene Ther       Date:  2019-03-29       Impact factor: 5.250

2.  Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy.

Authors:  Rodrigo Esaki Tamura; Rafael Bento da Silva Soares; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  Cancer Biol Ther       Date:  2016-09-19       Impact factor: 4.742

3.  Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy.

Authors:  Ruan F V Medrano; Thiago A Salles; Rafael Dariolli; Fernanda Antunes; Valker A Feitosa; Aline Hunger; João P P Catani; Samir A Mendonça; Rodrigo E Tamura; Marlous G Lana; Elaine G Rodrigues; Bryan E Strauss
Journal:  Sci Rep       Date:  2022-08-10       Impact factor: 4.996

Review 4.  Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer.

Authors:  Bryan E Strauss; Gissele Rolemberg Oliveira Silva; Igor de Luna Vieira; Otto Luiz Dutra Cerqueira; Paulo Roberto Del Valle; Ruan Felipe Vieira Medrano; Samir Andrade Mendonça
Journal:  Clinics (Sao Paulo)       Date:  2018-09-06       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.